SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is facing intense scrutiny and bearish sentiment from investors concerned about a lack of clear communication regarding the company's Helios data center progress and perceived mismanagement. Despite interest from institutional research desks, the stock is currently struggling with high volatility and underperformance, leading many in the community to express frustration over the silence from leadership during recent market fluctuations.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing intense bearish sentiment and significant downward pressure following weak revenue guidance and concerns over slowing demand in China. While the stock has hit multi-year lows, the community is deeply divided between those viewing the steep sell-off as a generational buying opportunity for a legacy brand and those warning that fundamental issues like brand relevance, inventory challenges, and declining quality make it a value trap.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is experiencing high volatility as investors track its history as a parabolic runner, leading to intense debate over whether it is primed for another short squeeze or remains a high-risk pump-and-dump scheme. Community discussion is heavily focused on the stock's low float, rising cost-to-borrow fees, and speculation regarding potential retail-driven "meme" momentum compared to its past price spikes.

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF (NASA) is gaining traction as a new, actively managed vehicle providing retail investors with exposure to the space economy, specifically through its allocation to SpaceX ahead of a highly anticipated IPO. Community members are actively debating the fund's growth potential and AUM size compared to similar products, with many using the ticker to gain exposure to space-sector tailwinds and upcoming lunar mission catalysts.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is surging following the announcement of a clinical development collaboration with Pfizer for its multiple myeloma candidate, alongside a private placement financing deal. The community is actively debating the stock's massive upside potential driven by this institutional endorsement and high short interest, while some traders caution against volatility as they watch for sustained volume to fuel a potential squeeze.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is drawing significant investor interest as the community weighs strong financial performance, including consistent earnings beats and strategic partnerships with industry giants like NVIDIA and Meta, against volatility surrounding its future growth guidance. Traders are actively debating the company's valuation as a "deep-value" AI infrastructure play, while monitoring technical levels for potential breakouts fueled by its expanding AI/HPC pipeline.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a surprise leadership overhaul that replaced CEO Peter Greenleaf with board chair Kevin Tang, a move widely interpreted by the community as a strategic catalyst for an accelerated company sale. Shareholders are actively debating whether Tangs decision to forgo compensation and his recent heavy accumulation of shares signals an imminent buyout or a shift toward aggressive value maximization.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on March 20, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings is gaining momentum as investors react to a newly granted patent for its real-time RF motion detection technology and ongoing strategic expansion into defense-focused AI and autonomous systems. The community is actively discussing the potential for a parabolic breakout, citing the stock's low float and recent high-profile institutional interest as catalysts for a potential squeeze.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is experiencing heightened investor interest and speculative momentum following the announcement of a multi-year AI cloud infrastructure contract. The community is actively discussing the company's low-float structure and potential for a short squeeze, with many users weighing the risks of volatility and lack of volume against the company's long-term enterprise pipeline.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing heightened volatility and intense social media debate as investors react to the company's pause in Bitcoin accumulation and ongoing concerns regarding stock dilution. The community remains deeply polarized, with bulls pointing to the company's long-term Bitcoin treasury strategy while vocal critics argue that the reliance on equity offerings to fund operations creates an unsustainable path for shareholders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UBS maintains Kymera Therapeutics $KYMR  at Buy and raises the price target from $90 to 
https://marketsblock.com/stock-upgrades-and-downgrades/

Today's stock upgrades and downgrades. Wall Street best analyst's price target for all the stocks. Goldman Sachs upgrades

MarketsBlock

Stock Upgrades and Downgrades - MarketsBlock

StockTwits Web

Kymera Therapeutics Inc

  at Buy and raises the price target from $90 to 
